繰延税金資産、減価償却費 - 医薬品開発支援、繰越利益剰余金
- 【期間】
| 年度 | 繰延税金資産 | 減価償却費 - 医薬品開発支援 | 繰越利益剰余金 |
|---|
| 2007/03 | - | | - | | 16.6億 | |
| 2008/03 | 10.4億 | | - | | 22.7億 | +36.7% |
| 2009/03 | 9.58億 | -8.1% | - | | 22.8億 | +0.2% |
| 2010/03 | 10.5億 | +9.9% | - | | 20.9億 | -8.4% |
| 2011/03 | 11億 | +4.2% | - | | 24.9億 | +19.3% |
| 2012/03 | 11.1億 | +0.9% | - | | 22.8億 | -8.3% |
| 2013/03 | 12.3億 | +10.7% | 174百万 | | 15.7億 | -31.2% |
| 2014/03 | 13.7億 | +12% | 83百万 | -52.4% | 18.1億 | +14.9% |
| 2015/03 | 7.96億 | -42% | 46百万 | -43.7% | 6.1億 | -66.2% |
| 2016/03 | 7.55億 | -5.2% | - | | 26.7億 | +337.4% |
| 2017/03 | 6.7億 | -11.3% | - | | 37.2億 | +39.5% |
| 2018/03 | 6.37億 | -4.9% | - | | 52.2億 | +40.2% |
| 2019/03 | 20.2億 | +217.2% | - | | 60.5億 | +15.8% |
| 2020/06 | - | | - | | 63.9億 | +5.7% |
| 2021/06 | - | | - | | 58.8億 | -8.1% |
| 2022/06 | - | | - | | 61.8億 | +5.2% |
| 2023/06 | - | | - | | 77.8億 | +25.8% |
